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More active high-dose regimens are needed for refractory/poor-risk relapsed lymphomas. We previously
developed a regimen of infusional gemcitabine/busulfan/melphalan, exploiting the synergistic interaction. Its
encouraging activity in refractory lymphomas led us to further enhance its use as a platform for epigenetic
modulation. We previously observed increased cytotoxicity in refractory lymphoma cell lines when the
histone deacetylase inhibitor vorinostat was added to gemcitabine/busulfan/melphalan, which prompted
us to clinically study this four-drug combination. Patients ages 12 to 65 with refractory diffuse large B cell
lymphoma (DLCL), Hodgkin (HL), or T lymphoma were eligible. Vorinostat was given at 200 mg/day to 1000
mg/day (days 8 to 3). Gemcitabine was infused continuously at 10 mg/m2/minute over 4.5 hours (days 8
and 3). Busulfan dosing targeted 4000 mM-minute/day (days 8 to 5). Melphalan was infused at 60 mg/
m2/day (days 3 and 2). Patients with CD20þ tumors received rituximab (375 mg/m2, days þ1 and þ8). We
enrolled 78 patients: 52 DLCL, 20 HL, and 6 T lymphoma; median age 44 years (range, 15 to 65); median 3
prior chemotherapy lines (range, 2 to 7); and 48% of patients had positron emission tomographyepositive
tumors at high-dose chemotherapy (29% unresponsive). The vorinostat dose was safely escalated up to 1000
mg/day, with no treatment-related deaths. Toxicities included mucositis and dermatitis. Neutrophils and
platelets engrafted promptly. At median follow-up of 25 (range, 16 to 41) months, event-free and overall
survival were 61.5% and 73%, respectively (DLCL) and 45% and 80%, respectively (HL). In conclusion, vor-
inostat/gemcitabine/busulfan/melphalan is safe and highly active in refractory/poor-risk relapsed lym-
phomas, warranting further evaluation.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
High-dose chemotherapy (HDC) with regimens such as
carmustine/etoposide/cytarabine/melphalan (BEAM) with
autologous stem cell transplantation (ASCT) is standard
treatment of chemosensitive relapsed lymphomas. Earlyedgments on page 1919.
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ty for Blood and Marrow Transplantation.randomized trials showed beneﬁt from HDC in chemo-
sensitive relapsed diffuse large B cell lymphoma (DLCL) in
the pre-rituximab era, as well as in Hodgkin’s lymphoma
(HL) [1-3]. However, the more recent CORAL trial
showed worse outcomes after BEAM  rituximab in DLCL
patients who relapsed after rituximab-cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) than previ-
ously seen in patients who relapsed after CHOP alone [4].
Furthermore, particularly poor outcomes were seen in pa-
tients with primary refractory or relapsed tumors with poor-
risk features, such as a ﬁrst complete remission (CR) < 12
months, secondary International Prognostic Index (IPI) at
Table 1
Treatment Schedule
Day . 9 8 7 6 5 4 3 2 1 0 þ1 þ8
Admission X
Vorinostat X X X X X X X
Gemcitabine X X
Busulfan x
(test)*
X X X X
Melphalan X X
PBPC X
Rituximab
(CD20þ tumors)
X X
PBPC indicates peripheral blood progenitor cells.
* Busulfan test dose to be administered in the week before admission.
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presence of active tumor at HDC [5-8]. Similar adverse
prognostic factors have been described for HL [9,10]. There-
fore, there is a clear need to develop more effective HDC
regimens for these patient populations.
We previously developed a high-dose combination of
gemcitabine/busulfan/melphalan (Gem/Bu/Mel), which
showed a synergistic interaction based on gemcitabine in-
hibition of DNA damage repair [11]. Gemcitabine was infused
at a ﬁxed dose rate of 10 mg/m2/minute, optimizing forma-
tion of its active intracellular triphosphate metabolite
[12,13]. Busulfan was administered intravenously with
pharmacokinetic-guided dosing. Gem/Bu/Mel showed
encouraging activity in lymphomas. An analysis of concur-
rent patient cohorts with refractory HL treatedwith Gem/Bu/
Mel, Bu/Mel, or BEAM, showed superior outcomes in the
Gem/Bu/Mel cohort despite a higher prevalence of poor-
prognosis features [14].
An important factor affecting the activity of DNA-
targeting agents is access to DNA. Changes in histone
acetylation lead to changes in chromatin conﬁguration. In-
hibition of histone deacetylases weakens the histone-DNA
bonds and decondenses chromatin [15]. In our prior pre-
clinical experiments in resistant B and T lymphoma cell lines,
a synergistic increase in cytotoxicity was observed when
the histone deacetylases inhibitor vorinostat (suberanilo
hydroxamic acid) was added to gemcitabine/busulfan/
melphalan combination [16]. We saw a signiﬁcant increase in
the g-H2AX level and cleavage of poly-[ADP-ribose]-
polymerase-1 (PARP-1), suggesting increased DNA damage
response and apoptosis, respectively [17]. Furthermore, there
was important sequence speciﬁcity, and concurrent treat-
ment was more active than sequential drug exposures.
These intriguing preclinical observations motivated us to
test vorinostat/Gem/Bu/Mel clinically. Prior studies have
shown that the duration of histone hyperacetylation is pro-
portional to vorinostat dose [18]. We hypothesized that vor-
inostat can be safely combined with Gem/Bu/Mel with ASCT.
We report here the results of our ﬁrst dose-ﬁnding study of
vorinostatwithGem/Bu/Mel inpatientswith refractory/poor-
risk relapsed Hodgkin’s and non-Hodgkin’s lymphomas.
PATIENTS AND METHODS
Patient Population
The study protocol was approved by the clinical research committee
and institutional review board of MD Anderson Cancer Center. Patients
provided written informed consent before enrollment. Eligibility included
ages 12 to 65 and 1 of the following lymphomas: (1) DLCL with primary
refractory disease (less than CR or induction failure after R-CHOP), relapse
within 12 months of R-CHOP, secondary IPI >1, less than partial response to
ﬁrst salvage chemotherapy, or prior treatment with  3 chemotherapy
lines; (2) HL with primary refractory disease (progression during or within
3 months of frontline chemotherapy), relapse within 12 months of frontline
chemotherapy, within a prior irradiation ﬁeld, extranodal, or bulky (deﬁned
as any lesion > 5 cm) disease, less than metabolic CR to second-line
chemotherapy, or second relapse or beyond; and (3) refractory/relapsed T
lymphoma. Additional eligibility criteria included adequate renal (creati-
nine clearance  50 mL/minute), hepatic (serum glutamic oxaloacetic
transaminase [SGOT]/serum glutamic pyruvic transaminase [SGPT]/bili-
rubin  3  upper normal limit, pulmonary (forced expiratory volume in 1
second [FEV1]/forced vital capacity [FVC]/corrected diffusing lung capacity
for carbon monoxide [cDLCO]  50%) and cardiac function (left ventricular
ejection fraction  40%), performance status 0 to 1, no prior whole brain
irradiation or radiation within 1 month of enrollment, no active hepatitis B,
and no chronic hepatitis C causing cirrhosis/stage 3 to 4 ﬁbrosis.
Tumors were restaged within 30 days before enrollment, at 1, 3, and 6
months after HDC, and every 6 months thereafter. Responses were assessed
before planned post-HDC radiotherapy. Positron emission tomography (PET)
scans were interpreted with mediastinal blood pool activity as reference
background [19].HDC
Patients received an intravenous test dose of busulfan of 32 mg/m2 over
60 minutes during the preadmission week (Table 1). Vorinostat was
administered from days 8 to2 at doses ranging from 200 to 1000 mg per
oral daily per cohort (Table 2) within 1 hour before the start of chemo-
therapy. Gemcitabine was administered on days 8 and 3 as a loading
bolus of 75 mg/m2 followed by a continuous infusion per cohort, immedi-
ately followed by busulfan or melphalan. Busulfan was infused daily over 3
hours from days 8 to5 targeting an average daily area under the curve of
4000 mM-minute, with the ﬁrst 2 therapeutic doses calculated from the
pharmacokinetics after the test dose. If necessary, the third and fourth doses
were readjusted after the ﬁrst therapeutic dose analysis, targeting an
aggregate course area under the curve of 16,000 mM-minute. The sampling
and analytical processes have been described previously [20,21]. A ﬁxed
busulfan dose of 100 mg/m2/day would be given in cases where pharma-
cokinetic dosing was not feasible. Melphalan was administered at 60 mg/
m2/day over 30 minutes on days 3 and 2.
Supportive Care
Acetaminophen, azoles, and metronidazole were avoided from day 10
to 1. Phenytoin 300 mg/day to 600 mg/day was given from day 9 to 4.
Dexamethasone 8 mg i.v. was given twice daily from day 9 to 2. Intra-
venous hydration started on admission until day 1. Oral care with
palifermin, glutamine, and supersaturated calcium/phosphate rinses, and
oral cryotherapy during melphalan, was performed uniformly as previously
described [11]. Infusion of peripheral blood progenitor cells was on day 0.
Departmental guidelines for post-transplantation ﬁlgrastim, antiemetics,
antimicrobials, and blood product transfusions were followed.
Trial Design
The primary endpoint was to determine the maximum tolerated dose of
vorinostat, up to a maximum planned dose (MPD) of 1000 mg/day, combined
withGem/Bu/Mel, basedondose-limiting toxicity (DLT), deﬁnedasanygrade4
nonhematological and noninfectious toxicity, or any grade 3mucositis or skin
toxicity lasting more than 3 days at peak severity. Secondary endpoints
included event-free survival (EFS), overall survival (OS), response, and CR rates
and to describe the toxicity proﬁle. Dose ﬁnding used the continual reassess-
mentmethodwith a target DLT probability per cohort of 20% [22]. In stage 1 of
the trial, doseswere chosen adaptively for successive cohorts ofminimumsize
2, up to dose level 11with aMPD of vorinostat of 1000mg/day (Table 2). If the
lowest dose level were found to be excessively toxic, the trial would move to
stage 2 using a lower dose of gemcitabine. Toxicity scoring followed the NCI
Common Toxicity Criteria, v3.0 [23].
Correlative Studies of DNA Damage Repair and Apoptosis
The phosphorylation status of histone 2AX (g-H2AX) and the level of
PARP-1 were determined in peripheral blood mononuclear cells from pa-
tients enrolled in this study at the highest dose of suberanilo hydroxamic
acid (1000 mg/day) and in separate trials of Gem/Bu/Mel and Bu/Mel, all of
which followed a parallel schedule from day 8 to 2 using the same drug
doses as in the present studies. Samples were collected at baseline, day 7
(1 hour after busulfan), and day 2 (1 hour after melphalan). The g-H2AX
level was measured by immunoﬂuorescent staining and ﬂow cytometry
using anti-g-H2AX antibody (EMD Millipore, Billerica, MA) [24]. Western
blot assay used protein extract separation on polyacrylamide-SDS gels and
blotting onto nitrocellulose membranes probed with antiePARP-1 (Santa
Cruz, Dallas, TX) and anti-b-actin (Sigma-Aldrich, St Louis, MO) antibodies.
Chemiluminescence immunoblot analysis used Immobilon Western
Chemiluminescent HRP Substrate (EMD Millipore). X-ray ﬁlms were scan-
ned with the EPSON Perfection V750 PRO and analyzed with UN-SCAN-IT
software (Silk Scientiﬁc, Orem, UT). PARP-1 bands were normalized
Table 2
Dose Escalation
Level Vorinostat
(mg/day)
Gemcitabine
(mg/m2/day)
Busulfan
(mm-min/day
or mg/m2/day)
Melphalan
(mg/m2/day)
Loading
Dose
Continuous
Infusion*
1 200 75 2100 4000 or 105 60
2 300 75 2100 4000 or 105 60
3 400 75 2100 4000 or 105 60
4 500 75 2100 4000 or 105 60
5 600 75 2100 4000 or 105 60
6 600 75 2400 4000 or 105 60
7 600 75 2700 4000 or 105 60
8 700 75 2700 4000 or 105 60
9 800 75 2700 4000 or 105 60
10 900 75 2700 4000 or 105 60
11 1000 75 2700 4000 or 105 60
* Continuous infusion of gemcitabine administered at 10 mg/m2/minute.
Table 3
Patient Characteristics (n ¼ 78)
Characteristic Value
Age: median (range), yr 44 (15-65)
Gender: Male/female 53/25
Primary refractory tumor/poor-risk or
refractory relapse
57%/43%
No. prior chemotherapy lines,
median, (range)
3 (1-7)
Prior radiotherapy, % 43%
Disease status at HDC: CR/PR/no
response, %
52%/22%/26%
PD at HDC 17%
Diagnoses
DLCL 52
Variants
NOS 39
T cell rich 4
Primary CNS 2
Anaplastic 2
Plasmablastic 2
Transformed 3
Double hit (% of DLCL) 10 (19%)
Cell of origin
Germinal center 15
Activated B cell 12
Primary mediastinal 8
Not determined 17
Primary refractory (%) (induction
PR/induction failure)
26 (50%) (14/12)
Relapsed (%) 26 (50%)
First relapse (%) 13 (25%)
Length of CR1: <12
months/12 months
6/7
Secondary IPI: 0-1/2/>3 6/6/1
Second relapse or later (%) 13 (25%)
Hodgkin’s 20
Primary refractory (% of Hodgkin’s) 13 (65%)
Poor-risk relapse 7
First relapse (%) 1 (CR1 12 months)
(5%)
Second relapse (%) 6 (30%)
Extranodal disease at relapse/PD 12
Bulky tumor at relapse/PD 11
B symptoms at relapse/PD 2
T-NHL 6
Histology (PTCL NOS/AITL/ALCL/NK-T) 2/2/1/1
Primary refractory/relapsed 4/2
PR indicates partial response; NOS, not otherwise speciﬁed; CNS, central
nervous system; PTCL, peripheral T-cell lymphoma; AITL, angioimmuno-
blastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; NK-T, nat-
ural killer T cell.
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1 between the groups used the t-test. A sample size of 15 patients in each
group offered 80% power to detect differences between the vorinostat/Gem/
Bu/Mel, Gem/Bu/Mel, and Bu/Mel groups, with estimated median relative
change in levels of g-H2AX and PARP-1 of 3 fold, 2 fold, and .5 fold,
respectively.
Statistical Methods
Overall response (OR) and CR rates were calculated among patients with
measurable disease at HDC following the usual criteria [25]. EFSwas deﬁned
as the time from transplantation to either relapse or death, whichever
occurred ﬁrst, or last contact. OS was deﬁned as the time from trans-
plantation to death or last contact. Kaplan-Meier survival curves estimated
unadjusted time-to-event distributions [26]. The log-rank test was used to
compare EFS and OS between subgroups [27]. Categorical variables were
compared by generalized Fisher’s exact test [28]. P values are 2 sided. All
calculations used R v2.12.1 and OpenBUGS v3.1.2 rev668.
RESULTS
Patient Enrollment
Seventy-eight patients were enrolled between September
2011 and November 2013 (Table 3). Median age was 44
(range, 15 to 65). Diagnoses were DLCL (n ¼ 52), HL (n ¼ 20),
and T non-Hodgkin lymphoma (T-NHL) (n ¼ 6). Patients had
received a median of 3 prior regimens (range, 2 to 7) and had
extensive tumor involvement (median, 3 organs). Of 52
patients with DLCL, 26 had primary refractory tumors, 13
were in ﬁrst relapse (6, 6, and 1 patients had a secondary IPI
of 0 to 1, 2 to 3, and >3, respectively), and 13 had >1 prior
relapse. Ten patients had double-hit DLCL. In the HL sub-
group, 13 patients (65%) had a primary refractory tumor, and
extranodal disease and bulky tumor at relapse/progressive
disease (PD) were present in 12 and 11 patients, respectively;
6 patients had >1 prior relapse. Four of 6 patients with
T-NHL had primary refractory disease. At HDC, 48% of all
patients had PET-positive tumors and 26% of patients had
unresponsive disease (PD in 17% of them).
Hematologic Recovery
The stem cell source was peripheral blood. Neutrophil
and platelets engrafted promptly at medians of 10 days
(range, 8 to 13) and 12 days (range, 8 to 55), respectively.
Regimen-Related Toxicities
Dose escalation of vorinostat proceeded from 200mg/day
(dose level 1) up to its MPD of 1000 mg/day (dose level 11),
combined with Gem/Bu/Mel (Table 2). The MPD level was
expanded to 22 patients to fully characterize its toxicity
proﬁle. No regimen-related deaths or grade 4 toxicities wereseen in the study. The side effect proﬁle of vorinostat/Gem/
Bu/Mel was as follows.
Mucositis
Grade 2 and 3 mucositis were observed in 45% and 32% of
patients, respectively, in levels 1 to 10, and in 48% and 38% of
patients, respectively, at level 11. It started at median day þ4
(range, day 0 toþ7), lasting at maximal severity for a median
of 3 (range, 1 to 9) days.
Dermatitis
Grade 1 and 2 erythematous rashes were common. Six
patients had a grade 3 rash, 2 of them at level 11. All cases
resolved spontaneously or with topical sunburn remedies or
topical steroids.
Hepatic effects
Early self-limited transaminase elevation was frequent
across all levels (6 patients grade 3, 21 patients grade 2),
starting on median day 1 (range, day 7 to 9), peaking at a
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Figure 1. Event-free (EFS) and overall survival (OS) curves. (A) DLCL subgroup
(n ¼ 52). (B) HL subgroup (n ¼ 20).
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week. Transient hyperbilirubinemia at median 2.1 mg/dL,
(range, 1.2 to 9.7) was seen in 51% patients in the ﬁrst week
after transplantation (12 patients grade 3, 19 patients grade
2), with no cases of veno-occlusive disease.
Pulmonary effects
DLCO decreased from before (median, 78.5% of predicted;
range, 52% to 152%) to 1 to 3 months after transplantation
(median, 71%; range, 31% to 150%) (P ¼ .002).There were 3
symptomatic cases of steroid-responsive grade 2 pneumonitis.
Other toxicities
Diarrheawasmild, with only 12 and 4 cases of grade 2 and
grade 3 diarrhea, respectively. Two patients experienced
grade 2 renal toxicity. No neurological or cardiac toxicities
were observed. Speciﬁcally, there was no QTc prolongation
from before HDC (median, 462; range 425 to 599 millisec-
onds) to day2 (median, 451; range 418 to 497milliseconds).
There was no correlation of preadmission values of
C-reactive protein, B-type natriuretic peptide, ferritin,
haptoglobin, or troponin with toxicity (data not shown).
Likewise, there was no signiﬁcant effect of age on toxicity
(data not shown).
Infections
Two patients had antibiotic-responsive methicillin-resis-
tant Staphylococcus aureus pneumonia. The following docu-
mented infections resolved with antimicrobials: Candidemia
(n ¼ 1), Stenotrophomonas bacteremia/urinary tract infection
(UTI) (n ¼ 1), S epidermidis bacteremia (n ¼ 1), cytomega-
lovirus pneumonia (n ¼ 1), respiratory syncytial virus upper
(n ¼ 1) and lower (n ¼ 1) respiratory infections, Herpes
simplex esophagitis (n ¼ 1), Enterococcus UTI (n ¼ 1), and
Pseudomonas aeruginosa UTI (n ¼ 1).
Busulfan Pharmacokinetic Studies
Busulfan pharmacokinetics were calculated in all pa-
tients. The overall mean of the variation of the calculated
test-to-therapeutic clearance was 6.3% (95% conﬁdence
interval, 9.9% to 19.5%). Only 3 patients showed a busulfan
clearance > 20% different when the ﬁrst and test doses were
compared. For the remaining 75 patients, the clearance
variation between the test and the ﬁrst therapeutic doses
was <20%. The mean (% coefﬁcient of variation) population
clearance, volume of distribution, and plasma half-life from
the ﬁrst therapeutic dose were 97 mL/minute/m2 (16.3%),
24.2 L/m2 (16%), and 2.9 hours (14.7%), respectively. These
population pharmacokinetics do not differ from those pre-
viously estimated with Bu/Mel [21] or Gem/Bu/Mel [11] (data
not shown).
Tumor Responses
The OR and CR rate among 28 patients with DLCL and
measurable disease were 96% and 73%, respectively. The OR
and CR rate among 14 patients in PD at the time of HDC were
100% and 64%, respectively.
Eight of 10 patients with measurable HL (5 of them in PD
at HDC) had a CR. Two of 2 patients with measurable T-NHL
(both in PD at HDC) experienced a CR.
Post-HDC Treatment
Seventeen patients (9 DLCL, 6 NHL, 1 T-NHL, 1 plasma-
blastic lymphoma [PL]) with pretransplantation bulky (>5
cm) PET-positive lesions received involved site radiotherapyto 30.6 to 42 Gy starting 1 to 2 months after transplantation,
with good tolerance. Irradiated sites were mediastinum (n ¼
8), axillary/supraclavicular lymph nodes (n ¼ 3), chest wall
(n¼ 2), thigh (n¼2), hip (n¼1), and splenectomybed (n¼ 1).
Patient Outcomes
Median follow-up is 25 months (range, 16 to 41). Only 1
relapse has occurred beyond 1 year after HDC. The EFS and
OS rates of the DLCL group were 61.5% and 73%, respectively
(Figure 1A). The fraction of patients alive in CR within the
different DLCL subgroups are 6 of 8 primary mediastinal, 6 of
10 double hit, 4 of 4 T cell rich, 2 of 2 plasmablastic, and 2 of 2
primary central nervous system. As per cell-of-origin type,10
of 15 patients in the germinal center and 8 of 12 patients in
the activated B cell categories remain in CR.
The EFS and OS rates among HL patients were 45% and
80%, respectively (Figure 1B). Lastly, 5 of 6 patients with
T-NHL were alive in CR at 16 to 29 months after HDC.
As expected, patients with PET-positive tumors had
worse EFS than those with PET-negative tumors at HDC, both
in the DLCL (50% versus 81%, P ¼ .01) (Figure 2A) and HL
groups (27% versus 73%, P ¼ .04) (Figure 2B).
DNA Damage Response and Apoptosis Studies
The levels of g-H2AX increased after Bu/Mel (n¼ 19) from
baseline to day 2 by a median 1.4-fold (Figure 3A). g-H2AX
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Figure 2. Event-free survival according to PET status at transplantation. (A)
DLCL subgroup. (B) HL subgroup.
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stat/Gem/Bu/Mel (n ¼ 18) by 5.8-fold and 5.1-fold, respec-
tively (P< .05 for each of these 2 groups compared to Bu/Mel,
P ¼ not signiﬁcant between them). These results suggest
activation of DNA damage response in patients who received
Gem/Bu/Mel  vorinostat, consistent with our previous
in vitro data.
The levels of PARP-1 of Bu/Mel patients did not change
signiﬁcantly on day7 (median, 1.2), and did only slightly on
day 2 (median, .5) (Figure 3B). A steeper day 7 drop
was observed after Gem/Bu/Mel (median, .5) and vorinostat/
Gem/Bu/Mel (median, .4). PARP-1 was undetectable on
day 2 in some Gem/Bu/Mel patients (median, .1) and in
almost all vorinostat/Gem/Bu/Mel patients (median, .0).
The relative baseline/day 2 PARP-1 decrease was more
pronounced after vorinostat/Gem/Bu/Mel compared with
after Gem/Bu/Mel (P ¼ .05) or Bu/Mel (P ¼ .003).
DISCUSSION
Our study shows that vorinostat can be safely added
to Gem/Bu/Mel. The schedule includes a daily dose of vor-
inostat, at its MPD of 1000 mg/day, preceding full doses of
Gem/Bu/Mel.
Conﬁrming our preclinical studies, we saw high activity of
vorinostat/Gem/Bu/Mel among patients with heavily pre-
treated and refractory lymphoma, mostly DLCL and HL. At a
median follow-up of 25 months, the EFS rates in these 2
groups are 64% and 45%, respectively. Although longer
follow-up is needed, these outcomes are encouraging, asmost relapses in these high-risk populations typically occur
early after transplantation [4-10]. Given the limitations of
this study, intrinsic to early clinical trials, these results
should be considered preliminary. Determining whether
vorinostat/Gem/Bu/Mel is superior to BEAM for any type of
lymphoma will need a randomized study.
Toourknowledge, this is theﬁrst reportof the combination
of an epigenetically active agent with HDC. This study builds
on our prior clinical work with Gem/Bu/Mel, a regimen
designed to exploit the synergistic inhibition exerted by
gemcitabine onDNAdamage repair [11]. The use of peripheral
blood progenitor cells circumvents the increased myelotox-
icity of infusional gemcitabine, allowing us to capitalize on its
increased antitumor activity, compared to shorter infusions of
this drug. Our prior observations of high activity of Gem/Bu/
Mel in lymphoid malignancies prompted us to use this
regimen as a platform for epigenetic HDC modulation. We
previously observed that vorinostat augmented the in vitro
cytotoxicity of gemcitabine, busulfan, and melphalan in
resistant lymphomaBcell andTcell lines [16]. This effect could
be, at least in part, mediated through activation of the DNA
damage response signalingpathway, as shownby increasedg-
H2AX [16]. The present observations in patient samples are
also indicative of increased genomic injury that may, among
other responses, lead to apoptosis. In our previous preclinical
experiments, apoptosis was detected by cleavage of PARP-1.
Interestingly, patients enrolled in this study experienced a
decrease or disappearance of PARP-1, rather than its cleavage.
Because PARP-1 is a DNA-repair protein [29], our present ob-
servations indicate a serious compromise of the ability of tu-
mor cells to repair drug-induced damaged DNA. Because
vorinostat has multiple effects on protein acetylation besides
histone acetylation, other potentiating mechanisms of the
effect of Gem/Bu/Mel are also possible.
Previous reports of vorinostat combined with standard-
dose chemotherapy in patients with various tumors
had shown more prolonged myelosuppression but no sig-
niﬁcant increase of nonhematological toxicities [30-33]. The
side effects of vorinostat/Gem/Bu/Mel in our study were
manageable, including mucositis, dermatitis, and clinically
silent elevation of liver function tests. This toxicity proﬁle is
similar to that we previously described with Gem/Bu/Mel
[11]. Buglio et al. reported an in vitro dose response effect of
vorinostat in lymphoma cell lines from 1 mM up to 5 mM [34].
By simple extrapolation from this range of in vitro levels, we
designed the dose escalation of vorinostat from 200 mg
(which results in a level of around 1 mM [18]) up to a MPD of
1000 mg (which approximately corresponds to 5 mM, the
upper limit of the range of concentrations where those
authors observed an in vitro dose-response effect) [34].
Because a daily dose of 1000 mg was well tolerated,
we consider it the dose of vorinostat to be combined with
Gem/Bu/Mel in future studies.
We did not observe DLTs at the MPD of vorinostat. It
would be useful to identify predictive markers of toxicity.
Previous reports have correlated high pretransplantation
values of C-reactive protein, ferritin, or brain natriuretic
peptide (BNP) with severe transplantation-related toxicity
[35-37]. Likewise, haptoglobin levels have been inversely
associated with gemcitabine hematological toxicity [38]. In
contrast, we could not establish any correlation between
those markers, or any patient characteristic, and toxicity. It is
possible that polymorphic genetic variation of relevant en-
zymes involved in the metabolism of Gem/Bu/Mel might
predict toxicity.
Figure 3. Representative cases of decrease in the level of PARP-1 in patients treated with Bu/Mel (A), Gem/Bu/Mel (B), and vorinostat/Gem/Bu/Mel (C).
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we previously estimated with Gem/Bu/Mel [11], indicating
no pharmacokinetic interaction between busulfan and
vorinostat.
In conclusion, vorinostat up to 1000mg daily can be safely
combined with Gem/Bu/Mel with ASCT. This regimen
induced high CR rates, promising early outcomes, and
encouraging correlative in vitro data from patients with
refractory or poor prognosis relapsed Hodgkin’s and NHL.
Further investigation of this combination is warranted.
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